L1 cell adhesion molecule (L1CAM) mRNA (L1CAM mRNA)

L1 cell adhesion molecule (L1CAM) mRNA is the transcript encoding a 200-220 kDa transmembrane glycoprotein of the immunoglobulin superfamily, which is vital for neuronal development, including neurite outgrowth and axonal guidance (UniProt P32004). In various aggressive malignancies, such as ovarian and endometrial cancers, the overexpression of L1CAM mRNA is strongly associated with poor prognosis, epithelial-mesenchymal transition (EMT), and increased metastatic potential (PubMed PMID: 23536145). Therapeutic strategies targeting L1CAM mRNA, such as small interfering RNAs (siRNAs) and antisense oligonucleotides (ASOs), aim to induce the degradation of the transcript or inhibit its translation, thereby reducing the levels of the pro-tumorigenic L1CAM protein (PubMed PMID: 19448669). These RNA-targeted interventions are being explored to overcome the limitations of monoclonal antibodies, particularly in reaching intracellular or sequestered pools of the protein. However, the physiological role of L1CAM in the central and peripheral nervous systems necessitates careful evaluation of potential neurotoxicities and off-target effects associated with systemic mRNA knockdown.

Other names

CD171L1CAML1HSASHSAS1MASAMIC5S10SPG1

RNA interference (RNAi) and antisense inhibition leading to targeted mRNA degradation and subsequent reduction in L1CAM protein translation.